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Acute Lymphoblastic Leukemia

Impact of cytogenetic abnormalities on
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acute lymphoblastic leukemia after allogeneic
hematopoietic stem cell transplantation:
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ABSTRACT

C

ytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis
in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities
on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with
Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/nonmyeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for
International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional
metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in
patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients
with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical
Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of
leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse
[hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95%
CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14)
predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41).
This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex
karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and
all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival
(P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in
ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a
potentially curative therapy for patients with acute lymphoblastic leukemia (ALL). Risk stratification of ALL
varies across studies and generally includes a spectrum of
demographic (e.g., age), clinical (e.g., white blood cell
count, minimal residual disease, steroid sensitivity), phenotypic (B- versus T-cell origin), and cytogenetic characteristics. Several cytogenetic risk stratification schemes have
been developed and are used as prognostic tools at diag1330

nosis of ALL to guide treatment decisions. However, most
prior studies focusing on the prognostic significance of
cytogenetics in ALL were influenced by inclusion of
patients with Philadelphia chromosome-positive (Ph+) BALL and defined for patients who received conventional
chemotherapies.
Pivotal Medical Research Council–Eastern Cooperative
Oncology Group (MRC-ECOG) and Southwest Oncology
Group (SWOG) clinical trials identified commonly recognized Ph-negative (Ph–) cytogenetic risks, including
KMT2A (MLL) translocations at 11q23 associated with
haematologica | 2020; 105(5)
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t(4;11)(q21;q23), complex karyotype, t(8;14)(q24;q32), low
hypodiploidy, or near triploidy, among others.1 However,
only a subset of Ph– patients underwent allogeneic HCT in
those trials. Thus, the applicability of existing cytogenetic
risk classifications for allogeneic transplant recipients with
ALL remains uncertain due to the relatively low frequency
of specific Ph– cytogenetic abnormalities and the modest
size of prior studies. In a single-center retrospective cohort
study of 333 allograft recipients with ALL, cytogenetic risk
did not predict survival after allogeneic HCT.2 Notably, in
that study Ph+ patients accounted for the majority of
patients in the poor-risk cytogenetic group, and the cytogenetic risk scheme used was chosen arbitrarily. Another
study on allogeneic HCT in Ph– ALL (n=373), conducted in
Japan, found no difference in overall survival between
patients with high-risk [t(4;11), t(8;14), low hypodiploidy,
and complex karyotype] and standard-risk cytogenetics.3
A more recent analysis of Ph– B-ALL patients from
GRAALL clinical trials identified t(4;11)/KMT2A-AFF1 and
t(v;14q32)/IGH as markers of poor clinical outcome; however, only a third of the trial patients underwent allogeneic
HCT in first complete remission.4
In view of the conflicting prior data, we analyzed
Center for International Blood and Marrow Transplant
Research (CIBMTR) registry data to determine the prognostic impact of individual conventional (G-banding)

cytogenetic abnormalities and major previously established Ph– cytogenetic risk classifications (Table 1) on
outcomes of allogeneic HCT. We also developed an allogeneic HCT‐specific cytogenetic classification of Ph–
ALL for prediction of post-transplant relapse and survival.

Methods
Data source
Study data were obtained from the CIBMTR registry
which is a voluntary network of over 450 blood and marrow transplant centers in the USA and around the world.
Participating centers contributed detailed transplant-related information longitudinally to the centralized data
management and statistical centers at the Medical
College of Wisconsin (Milwaukee, WI, USA) and the
National Marrow Donor Program (NMDP) (Minneapolis,
MN, USA). Like all observational research conducted by
the CIBMTR, this study adhered to strict federal regulations for the protection of human research subjects.
Protected health information used in this study was collected and maintained in CIBMTR’s capacity as a Public
Health Authority under the Health Insurance Portability
Accountability (HIPAA) Privacy Rule.

Table 1. Major established cytogenetic risk classifications of Philadelphia chromosome-negative acute lymphoblastic leukemia.

Study

Design highlights

Risk group

Cytogenetic abnormalities

MRC-ECOG (Moorman et al.
Blood 2007)

• Randomized phase III
• 796 pts with abnormal
cytogenetics
• 310 alloHCT

Poor

t(4;11), t(8;14)*, complex* (≥5 abnormalities without
translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)*
All other karyotypes

Modified MRC-ECOG
(Pullarkat et al. Blood 2008)

SWOG (Pullarkat et al.
Blood 2008)

NILG-ALL (Bassan et al.
Blood 2009)

• Randomized phase III
• 140 pts with evaluable
cytogenetics
• Re-classified by MRC-ECOG
• 19 alloHCT

• Randomized phase III trial
• 140 pts with evaluable
cytogenetics
• 19 alloHCT
• Phase II
• 276 with evaluable cytogenetics

Other
Good
Very high
High
Intermediate

Standard
Unfavorable
Miscellaneous
Normal
Adverse
Non-adverse

North UK (Moorman et al.
Blood 2010)

• Observational
• 292 pts with evaluable cytogenetics

Normal
Poor

Standard
GIMEMA 0496 (Mancini et al. • Phase II
High
Blood 2005)
• 282 pts with evaluable cytogenetics Intermediate
Standard

High hyperdiploidy (>50), del(9p)
t(4;11), t(8;14), complex (≥5 abnormalities without
translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)
Other 11q23/MLL, monosomy 7§, del(7p), +8§, t(1;19) or t(17;19),
t(5;14)
Normal diploid, low hyperdiploidy (47-50 chr), abnormal 11q (not
MLL), del(6q), del(17p), del(9p), del(12p), del(13q), t14q32,
t(10;14), tetraploidy (>80 chr), or any karyotype abnormalities not
identified with a different risk group
High hyperdiploidy (>50 chr)
Monosomy 7, +8, and 11q23/MLL gene rearrangements
Any other abnormal karyotype
Normal karyotype
t(4;11) and/or MLL-AF4, +8, near triploidy, low hypodiploidy,
complex (≥3 abnormalities), del(6q), t(8;14)
t(1;19) and/or E2A-PBX1, hyperdiploid, other karyotype
abnormalities not identified with a different risk group
Normal karyotype
t(4;11), t(8;14), t(14;18), complex (≥5 abnormalities without
translocations), low hypodiploidy (30-39 chr)/near triploidy (60-78 chr)
All other karyotypes
t(4;11), t(1;19)
del(6q) and other karyotypes
normal karyotype, del(9p)

MRC-ECOG: Medical Research Council-Eastern Cooperative Oncology Group; SWOG: Southwest Oncology Group; NILG: Northern Italy Leukemia Group; GIMEMA: Gruppo Italiano Malattie
EMatologiche dell'Adulto; alloHCT: allogeneic hematopoietic cell transplantation; pts: patients; chr: chromosomes; MLL: mixed lineage leukemia *Independent predictors. §Unfavorable
by Cancer and Leukemia Group B classification.
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Selection of patients

The initial study population included 3,275 adults (age ≥16
years) with Ph– ALL in first or second complete remission (CR1 or
CR2, corresponding to morphological remission with <5% bone
marrow blasts) who underwent allogeneic HCT between 19952011 and whose data were reported to the CIBMTR. Further
restriction of the study population to the recipients of HLAmatched sibling and unrelated donor peripheral blood or bone
marrow allografts (with consent to submit at least 100 days of
post-transplant research reports) resulted in 2,903 eligible study
participants. The CIBMTR data center requested original cytogenetic reports for cases with reportedly abnormal or unknown
cytogenetics at either the time of diagnosis or prior to allogeneic
HCT. Cytogenetic reports were received from participating centers for 1,013 cases, all of which were reviewed and validated by
the study’s principal investigators (AL, MD). Data on cytogenetics
from the existing CIBMTR records were used for 743 cases for
which no original cytogenetic reports were received from the
queried centers. For 342 cases (12%) with prior CIBMTR cytogenetics status reported as “unknown” or “not tested” the original
cytogenetic reports were requested, but not received from the
transplant centers. Normal conventional cytogenetic results were
confirmed with over 95% accuracy upon review of all original
reports received and the remaining 805 cases with normal cytogenetics were included in the final study sample of 1,099 patients
with normal cytogenetics reported. Patients with abnormal conventional cytogenetics (n=632) were included in the study population after review of all available original cytogenetic reports. Thus,
a total study population of 1,731 patients from 256 reporting centers and 38 countries was analyzed.

Cytogenetics
Blood and marrow samples at the time of ALL diagnosis and
prior to transplantation were cultured and evaluated for cytogenetic abnormalities by G-banding according to the standard practices of the participating centers. Original cytogenetic data reported to the CIBMTR conformed to the International System of
Cytogenetic Nomenclature (ISCN).5 According to the ISCN, a
clonal abnormality was defined as the presence of a gain of the
same chromosome or the presence of the same structural abnormality in ≥2 cells or the loss of the same chromosome in ≥3 cells.
A normal conventional cytogenetic result was defined as the
absence of clonal abnormalities in at least 20 metaphase cells.
Abnormal cytogenetics were classified according to previously
established cytogenetic risk classifications for Ph– ALL (Table 1).
Standard definitions for hypodiploid, hyperdiploid, complex, and
monosomal karyotypes were based on the following modal chromosome numbers: (i) low hypodiploidy (30-39 chromosomes), (ii)
high hypodiploidy (40-43), (iii) low hyperdiploidy (47-50), (iv)
high hyperdiploidy (>50), (v) near triploidy (60-78), (vi) tetraploidy
(>80), (vii) complex with ≥5 abnormalities6-8 (adopted here) in the
absence of established translocations or ploidy abnormalities; or
≥3 abnormalities used exclusively by the Northern Italy Leukemia
Group (NILG)9 (Table 1), and (viii) monosomal (≥2 autosomal
monosomies or a single autosomal monosomy combined with a
single structural abnormality). Fluorescence in situ hybridization
(FISH) findings and/or other molecular data were available for the
minority of patients and were, therefore, only used to validate
cytogenetic reports when available.

Statistical analysis
Individual Ph– cytogenetic abnormalities were included in the
analysis if they were detected in ≥20 patients or in <20 patients
but with previously established prognostic significance in ALL.
1332

Cytogenetic abnormalities included high hyperdiploidy (n=29),
tetraploidy (n=9), near triploidy (n=6), low hypodiploidy (n=11),
complex karyotype (n=51), monosomal karyotype (n=84), monosomy 17 (n=21), i(17q) (n=5), del(17p) (n=6), t(1;19) (n=33), t(4;11)
(n=95), t(8;14) (n=10), t(10;11) (n=8), t(11;19) (n=10), add(5q) (n=7),
del(5q) (n=20), add(7p) (n=8), i(7q) (n=10), add(12p) (n=10),
del(12p) (n=18), t(14;18) (n=6), del(6q) (n=48), del(7q) (n=7), monosomy 7 (n=33), add(9p) (n=11), del(9p) (n=52), i(9q) (n=17),
add(12p) (n=10), del(12p) (n=18), del(11q) (n=18), del(13q) (n=12),
and trisomy 8 (n=35). Each cytogenetic abnormality was tested
individually for its association with post-HCT relapse while
adjusted for potential confounders. Statistically significant
(P<0.05) clinical factors other than cytogenetics [conditioning regimen, remission status, donor type, and graft-versus-host disease
(GvHD) prophylaxis among other potential confounders] were
retained in the multivariable Cox proportional hazards model.
Abnormalities with a hazard ratio (HR) ≥1.4 for relapse were subsequently grouped as adverse risk; abnormalities with a HR ≤0.6
for relapse were grouped as favorable, whereas all other abnormalities, and normal cytogenetics, were grouped as intermediate
risk. Relapse was used as the primary endpoint for evaluation of
individual cytogenetic abnormalities and it was calculated as the
cumulative incidence of ALL recurrence with treatment-related
mortality as the competing risk. Leukemia-free survival was used
as the primary endpoint for evaluation of previously established
and study-derived cytogenetic risk classifications and was defined
as the time to death or relapse with survivors in continuing complete remission censored at last follow-up. Adjusted probabilities
of leukemia-free survival and relapse were calculated using multivariable models, stratified by cytogenetic risk scheme and weighted by the pooled sample proportion value for each prognostic factor.10,11 Overall survival was a secondary study endpoint and was
defined as the time to death from any cause with surviving
patients censored at last follow-up. Treatment failure (1 –
leukemia-free survival) and overall mortality (1 – overall survival)
were used to model all Cox regression HR estimates. SAS version
9.4 (SAS Institute, Cary, NC, USA) and GraphPad Prism version
7.04 were used for all data analysis and graphics.

Results
Study population and transplant characteristics
A description of the entire study population and the distribution of the main study variables among patients with
abnormal and normal cytogenetics are summarized in
Table 2. The study cohort consisted predominantly of
young (82% <45 years) male (63%) patients with B-precursor ALL (69%). Patients with hyperleukocytosis (white
blood cell count >30×109/L for B-ALL and >100×109/L for
T-ALL) at the time of initial diagnosis accounted for 22%
of the entire cohort and 57% of patients underwent allogeneic HCT in CR1 with a median time to achieve CR1 of
6 weeks (range, 1-123).

Post-transplant outcomes classified by established
cytogenetic schemes
Patients with abnormal cytogenetics had 5-year
leukemia-free and overall survival rates of 40% and 42%,
respectively, which were similar to those of patients with
a normal karyotype (both P>0.6). The cytogenetic risk categories defined by the MRC-ECOG, SWOG, NILG-ALL,
North UK, and GIMEMA 0496 (Table 1) had no prognostic
significance for leukemia-free survival, relapse, or overall
survival (all P-values >0.15). However, the cytogenetic risk
haematologica | 2020; 105(5)

Ph– ALL cytogenetics and allogeneic HCT outcomes

Table 2. Patient and transplant characteristics.

Variables

All

continued from previous column

Cytogenetics Cytogenetics
Abnormal
Normal

Number of patients
1731
632 (36.5)
Number of centers
256
178
Recipient age, median (range), years 29 (16-68)
28 (16-65)
Gender, female, n (%)
636 (37)
234 (37)
Recipient race, n (%)
Caucasian
1429 (83)
534 (84)
African-American
42 (2)
12 (2)
154 (9)
49 (8)
Asian
Other
106 (7)
37 (6)
Karnofsky score ≥ 90%, n (%)
1245 (72)
459 (73)
Disease status prior to alloHCT, n (%)
CR1
990 (57)
395 (62.5)
CR2
741 (43)
237 (37.5)
Time to CR1, median (range), weeks 6 (1-123)
5 (2-123)
3 (<1-16)
3 (<1-13)
Time from CR1 to alloHCT1, median
(range), months
Time from CR1 to relapse2,
20 (<1-111) 18 (<1-103)
median (range), months
ALL lineage, n (%)
B-ALL
1197 (69)
474 (75)
T-ALL
393 (23)
121 (19)
Unknown
141 (8)
37 (6)
Hyperleukocytosis at diagnosis, n (%)
B-ALL (>30x109 WBC/L)
299 (17)
150 (24)
T-ALL (>100x109 WBC/L)
81 (5)
31 (5)
Extramedullary ALL at diagnosis, n (%)
CNS
105 (6)
35 (6)
Non-CNS
202 (12)
70 (11)
Conditioning intensity, n (%)
MAC (+TBI)
1343 (78)
522 (83)
MAC (-TBI)
254 (15)
72 (11)
NMA/RIC
98 (6)
28 (5)
Unknown
36 (2)
10 (2)
GvHD prophylaxis, n (%)
Tacrolimus-based
576 (33)
217 (34)
Cyclosporine A-based
1000 (58)
350 (55)
T-cell depletion (ex-vivo)
123 (7)
55 (9)
In-vivo T-cell depletion, n (%)
Alemtuzumab
46 (3)
19 (3)
ATG
286 (17)
99 (16)
Graft source, n (%)
Bone marrow
790 (46)
281 (44)
Peripheral blood
941 (54)
352 (46)
Donor type, n (%)
HLA-identical sibling
819 (47)
270 (43)
Well-matched unrelated donor
469 (27)
188 (30)
Partially-matched/mismatched
357 (21)
141 (22)
unrelated donor
Other related/unrelated donor
172 (10)
70 (11)
Donor/recipient CMV serostatus, n (%)
Donor+/recipient+
574 (33)
170 (27)
Donor+/recipient193 (11)
78 (12)
Donor-/recipient+
385 (22)
143 (23)
Donor-/recipient494 (29)
210 (33)
Unknown
85 (5)
31 (5)
Donor/recipient gender match, n (%)
Male-male
691 (40)
256 (41)
Male-female
340 (20)
127 (20)

1099 (63.5)
226
29 (16-68)
402 (37)
895 (81)
30 (3)
105 (10)
69 (6)
786 (72)
595 (54)
504 (46)
6 (1-113)
4 (<1-16)
21 (1-111)

723 (66)
272 (25)
104 (9)
149 (14)
50 (4)
70 (6)
132 (12)
821 (75)
182 (17)
70 (7)
26 (2)
359 (33)
650 (59)
68 (6)
27 (2)
187 (17)
509 (46)
590 (54)
549 (50)
281 (26)
216 (20)
102 (9)
404 (37)
115 (10)
242 (22)
284 (26)
54 (5)
435 (40)
213 (19)

continued in next column
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Female-male
Female-female
Unknown
Year of alloHCT, n (%)
1995-2000
2001-2005
2006-2011
Median follow up of survivors
(range), months

401 (23)
295 (17)
4 (<1)

142 (22)
107 (17)
0

259 (24)
188 (17)
4 (<1)

557 (32)
604 (35)
570 (33)

194 (31)
217 (34)
221 (35)

363 (33)
387 (35)
349 (32)

75 (2-224)

87 (3-224)

73 (2-218)

alloHCT: allogeneic hematopoietic cell transplantation; CR1: first complete remission; CR2:
second complete remission; ALL: acute lymphoblastic leukemia; WBC: white blood cell; CNS:
central nervous system; MAC: myeloablative conditioning; TBI: total body irradiation; NMA:
non-myeloablative; RIC: reduced-intensity conditioning; HLA: human leukocyte antigen;
GvHD: graft-versus-host disease; ATG: antithymocyte globulin; CMV: cytomegalovirus.1Referred
to patients in CR1. 2Referred to patients in CR2.

classification defined by the modified MRC-ECOG was
significantly associated with both treatment failure (overall P=0.02) and overall survival (overall P=0.03) in multivariable analyses adjusted for recipient age, disease status,
conditioning intensity, Karnofsky Performance Status,
donor type, and GvHD prophylaxis (Figures 1A and 2).
Significant associations between the modified MRCECOG classification and major clinical outcomes
appeared to be largely driven by the favorable outcomes
of patients with standard-risk cytogenetics (n=24), all with
a high hyperdiploid karyotype. There was no difference
between high or very high modified MRC-ECOG cytogenetic risk groups compared to the intermediate group. In
contrast, good-risk cytogenetics according to the MRCECOG classification included del(9p), in addition to high
hyperdiploidy, and was not significantly associated with
any of the clinical outcomes of interest.

Individual cytogenetic abnormalities: relapse
Monosomy 7 [HR=2.11; 95% confidence interval (CI):
1.04-4.27, P=0.04] and complex karyotype (HR=1.69; 95%
CI: 1.06-2.69, P=0.03) were both associated with
increased risk of relapse in multivariable analysis adjusted
for conditioning intensity, ALL remission status prior to
transplantation, and monosomal karyotype (Figure 3,
Table 3). Patients with high hyperdiploidy had an estimated 54% lower risk of relapse, whereas those with del(7q),
t(8;14), t(11;19), del(11q), or a tetraploid/near triploid karyotype had a HR of at least 40% higher for relapse, which
did not reach statistical significance (Figure 3). The magnitude and strength of associations with relapse for the
remaining individual cytogenetic categories, such as trisomy 8, monosomal karyotype, monosomy 17,
del(17p)/i(17p), low hypodiploidy, del(6q), t(1;19), t(4;11),
and normal karyotype, did not demonstrate any meaningful clinical associations (all HR between 0.6 and 1.4), and
none was statistically significant (all P-values >0.1).
A significant interaction was detected between t(4;11)
and pre-transplant remission status (P<0.001) with the
adverse impact of t(4;11) on relapse observed only in
patients undergoing allogeneic HCT in CR2 (HR=2.82;
95% CI: 1.25-6.36, P=0.01), but not in CR1 (HR=0.86,95%
CI: 0.53-1.41, P=0.55).

Individual cytogenetic abnormalities: treatment failure
Monosomy 7 (HR=1.97; 95% CI: 1.20-3.24, P=0.007)
and t(8;14) (HR=2.85; 95% CI: 1.35-6.02, P=0.006) were
1333
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prognostic for treatment failure after adjustments for
recipient age, pre-transplant remission status, conditioning intensity, donor type, and GvHD prophylaxis in multivariable analyses (Table 4). Trends toward increased risk
of treatment failure were observed for patients with
del(7q) (HR=2.16; 95% CI: 0.95-4.90, P=0.06) and
del(17p)/i(17q) (HR=1.95; 95% CI: 0.80-4.75, P=0.1). In
contrast, patients with high hyperdiploidy (HR=0.62; 95%
CI: 0.37-1.04, P=0.07) and monosomal karyotype
(HR=0.73; 95% CI: 0.54-1.01, P=0.05) trended toward less
risk of treatment failure. Although t(4;11) was not associated with treatment failure (HR=1.12; 95% CI: 0.85-1.48,
P=0.41) within the entire cohort or in CR1 patients (n=83)
(HR=0.98; 95% CI: 0.72-1.33, P=0.89), it was associated
with a significantly higher risk of treatment failure in CR2
patients (n=11) (HR=2.35; 95% CI: 1.25-4.43, P=0.008).

Individual cytogenetic abnormalities: overall mortality
After adjustment for recipient age (HR=1.55; 95% CI:
1.17-2.06, P<0.01 for age >55 years versus <40 years),

Karnofsky Performance Status <90 (HR=1.29; 95% CI:
1.12-1.48, P<0.001), ALL in CR2 (HR=1.56; 95% CI: 1.361.77, P<0.001), myeloablative conditioning without total
body irradiation (HR=1.35; 95% CI: 1.13-1.62, P<0.001),
mismatched unrelated donor (HR=1.49; 95% CI: 1.271.76, P<0.001), and GvHD prophylaxis (HR=1.41; 95% CI:
1.11-1.79, P=0.005 for non-calcineurin inhibitor- versus
tacrolimus-based) in multivariable analysis, only t(8;14)
was associated with higher mortality after allogeneic HCT
(HR=3.03; 95% CI: 1.44-6.41, P=0.004).

Novel allogeneic hematopoietic cell transplantationspecific cytogenetic classification
Based on the relapse model adjusted for significant clinical factors and individual cytogenetic abnormalities
(Figure 3), the following cytogenetic markers with
HR≥1.4 were categorized as adverse risk (n=125): monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19),
del(11q), and tetraploid/near triploid karyotype.
Conversely, high hyperdiploidy (n=29) was identified as

A

B

Figure 1. Adjusted leukemia-free survival by cytogenetic risk classifications. (A) Adjusted leukemiafree survival by modified Medical Research Council
– Eastern Cooperative Oncology Group cytogenetic
risk classification. (B) Adjusted leukemia-free survival by Center for International Blood and Marrow
Transplant Research acute lymphoblastic leukemia
risk classification. HCT: hematopoietic cell transplantation.
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the sole cytogenetic abnormality with a HR≤0.6 for
relapse, and was categorized as favorable risk. The
remaining cytogenetic markers, including normal cytogenetics, were categorized as intermediate risk (n=1566).
This novel allogeneic HCT-specific cytogenetic risk classification (hereafter called CIBMTR ALL risk) was found
to be prognostic for both post-transplant relapse (Online
Supplementary Figure S1) and leukemia-free survival (logrank P=0.04) (Figure 1B). Furthermore, in the multivariable Cox proportional hazards model adjusted for recipient age, pre-transplant remission status, conditioning
intensity, Karnofsky Performance Status, donor type, and
GvHD prophylaxis, patients with CIBMTR adverse-risk
cytogenetics had a higher risk of treatment failure
(HR=1.26; 95% CI: 1.01-1.57, P=0.04), and those with
favorable risk had a lower risk (HR=0.6; 95% CI: 0.351.02, P=0.06) compared to those with intermediate-risk
cytogenetics (Table 5). There was a significantly greater
risk of treatment failure in those with adverse versus
favorable risk cytogenetic abnormalities (HR=2.10; 95%
CI: 1.19-3.70, P=0.01). Similarly, there was a significantly
greater risk of overall mortality in patients with adverse
versus favorable risk cytogenetic abnormalities (HR=1.91;
95% CI: 1.08-3.38, P=0.03).

Discussion
This large CIBMTR analysis of allogeneic HCT recipients with Ph– ALL defined a cytogenetic classification specific to allogeneic transplantation. Of the established
Table 3. Multivariable model of prognostic factors for post-transplant
relapse.

Factors

N

Conditioning regimens
MAC (+TBI)
1334
MAC (-TBI)
253
RIC/NMA
96
Remission status pre-alloHCT
CR1
986
CR2
733
Cytogenetics
Complex karyotype*
51
Monosomy 7*
33

HR (95% CI)

P-value

1.0
1.54 (1.22-1.96)
1.9 (1.38-2.61)

<0.001
<0.001

1.0
1.71 (1.44-2.04)

<0.001

1.69 (1.06-2.69)
2.11 (1.04-4.27)

0.03
0.04

N: number; HR: hazard ratio; 95% CI: 95% confidence interval; MAC: myeloablative conditioning; TBI: total body irradiation; RIC: reduced-intensity conditioning; NMA: non-myeloablative; alloHCT: allogeneic hematopoietic cell transplantation; CR1: first complete
remission; CR2: second complete remission. *Adjusted for monosomal karyotype.

Figure 2. Cytogenetic risks by modified Medical Research Council – Eastern Cooperative Oncology Group cytogenetic risk classification and post-transplant outcomes. All multivariable models were adjusted for recipient age, disease status, conditioning intensy, Karnofsky Performance Status, donor type and graft-versushost disease prophylaxis. mMRC-ECOG: modified Medical Research Council-Eastern Cooperative Oncology Group classification with its three cytogenetic risk
groups on Y-axis, relative to the Intermediate risk (reference with HR=1) on X-axis; LFS: leukemia-free survival; OS: overall survival.

Figure 3. Forest plots of cytogenetic markers associated with post-transplant relapse. All hazard ratios (HR) and corresponding 95% confidence intervals (CI) are
adjusted for conditiong intensity and remisssion status; CK: complex karyotype; N: sample size of carriers of each cytogenetic marker. * Defined as 40% risk increase
or decrement; **Markers with P<0.05; ΨAdjusted also for complex karyotype. DAdjusted also for monosomal karyotype.
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major ALL cytogenetic risk schemes, only the modified
MRC-ECOG classification could be validated in our
dataset for its association with post-transplant outcomes.
The association of the modified MRC-ECOG classification was largely explained by favorable outcomes for
patients with high hyperdiploidy, a factor known to be
associated with better outcomes.12,13 While a few individual high-risk cytogenetic abnormalities maintained their
prognostic relevance for recipients of allogeneic HCT,
many others had no significant prognostic influence on
the transplant outcomes. Thus, the aggregate effects of
previously established high or very high risk cytogenetic
groups defined by MRC-ECOG, SWOG, NILG-ALL,
North UK, and GIMEMA 0496 were overcome by allogeneic HCT and did not predict the outcomes of the transplant recipients. High-risk cytogenetic abnormalities
including trisomy 8, low hypodiploidy, t(1;19), del(6q)
could be overcome, in part, by the graft-versus-leukemia
effect of allogeneic HCT, and thus, were not unfavorable
in this analysis. In contrast to findings in acute myeloid
leukemia14,15 and recently reported cases of ALL,4,16 in our
dataset and elsewhere,17 monosomal karyotype did not
predict poor post-transplant outcomes for Ph– ALL.
Similarly, our analysis did not confirm the adverse effect
of t(4;11) on relapse or leukemia-free survival among all
carriers of this well-known cytogenetic risk, but uncovered a differential effect of t(4;11) on transplant outcomes
which was modified by pre-transplant disease status.
Nevertheless, given the relatively small subset of patients
with t(4;11) in CR2, the results of our post-hoc analysis
should be interpreted with caution. Moreover, the infrequency of CR2 allografts in patients with t(4;11) may
reflect intrinsic difficulty for those patients to effectively
maintain maintain subsequent remissions. A recent comparison of allograft recipients with t(4;11) and normal
karyotype in CR1 demonstrated relatively favorable survival of patients with t(4;11) and especially those with
undetectable pretransplant minimal residual disease.18
Allogeneic HCT in CR1 for adult ALL patients with t(4;11)
remains valuable.19
High-risk cytogenetic abnormalities found in this study
included t(8;14), complex karyotype, and monosomy 7,
previously known poor-risk categories in major classification schemes, excluding GIMEMA 0496 (Table 1).
Patients with these high-risk cytogenetic abnormalities
were predominantly young adults, most of whom
received myeloablative conditioning and still had poor

outcomes, thus confirming the high-risk nature of cytogenetic abnormalities.
The t(8;14) is a rare recurrent abnormality among
patients with ALL20-23 and has been associated with a poor
outcome.7 It was observed in ten allogeneic HCT recipients (median age, 21) who had a nearly 3-fold significantly
lower leukemia-free survival in our cohort. In addition to
the IGH-MYC fusion resulting from the t(8;14), other IGH
translocations involving BCL2 (when present together

Table 4. Multivariable model of prognostic factors for post-transplant
treatment failure.

Factors

HR (95% CI)

P-value

1.0
1.21 (1.04-1.41)
1.42 (1.07-1.88)

0.02
0.01

1.0
1.53 (1.34-1.74)

<0.001

N

Age, years
16-39
1270
40-55
363
55+
86
Remission status pre-alloHCT
CR1
986
CR2
733
Conditioning regimens
MAC (+TBI)
1334
MAC (-TBI)
253
MAC (+TBI)
1334
RIC/NMA
96
Performance status
KPS≥90
1234
KPS<90
423
Donor type
MSD
818
Matched URD
464
Mismatched URD
351
Other RD/URD
86
GvHD prophylaxis
Tac-based
569
CsA-based
996
Other
134
Cytogenetics
t(8;14)
10
Monosomy 7*
33

1.0
1.4 (1.18-1.66)
1.0
1.26 (0.97-1.64)

<0.001
0.09

1.0
1.32 (1.15-1.52)

<0.001

1.0
1.06 (0.9-1.24)
1.43 (1.21-1.68)
1.36 (1.02-1.81)

0.49
<0.001
0.03

1.0
1.11 (0.96-1.28)
1.39 (1.1-1.75)

0.15
0.006

2.85 (1.35-6.02)
1.97 (1.2-3.24)

0.006
0.007

N: number; HR: hazard ratio; 95% CI: 95% confidence interval; alloHCT: allogeneic
hematopoietic cell transplantation; CR1: first complete remission; CR2: second complete remission; MAC: myeloablative conditioning; TBI: total body irradiation; RIC:
reduced-intensity conditioning; NMA: non-myeloablative; KPS: Karnofsky Performance
Status; MSD: matched sibling donor; RD: related donor; URD: unrelated donor; GvHD:
graft-versus-host disease; CSA: cyclosporine. *Adjusted for monosomal karyotype.

Table 5. Novel Center for International Blood and Marrow Transplant Research risk scheme for post-transplant Philadelphia-negative acute lymphoblastic leukemia outcomes

Cytogenetic risk groups
Favorable (high hyperdiploidy)
Intermediate (normal karyotype
and all other abnormalities§)
Adverse (monosomy 7, complex karyotype,
del(7q), t(8;14), t(11;19), del(11q),
tetraploidy/near triploidy)
Adverse vs. favorable

N
Treatment failure(1-LFS)

HR (95% CI)*
Relapse

Overall mortality (1-OS)

28
1578

0.6 (0.35-1.02)
1.0 (Reference)

0.39 (0.15-1.05)
1.0 (Reference)

0.64 (0.37-1.08)
1.0 (Reference)

125

1.26 (1.01-1.57)

1.48 (1.09-2.0)

1.22 (0.97-1.53)

-

2.1 (1.19-3.7)

3.78 (1.36-1.76)

1.91 (1.08-3.38)

HR: hazard ratio; 95% CI: 95% confidence interval; LFS: leukemia-free survival; OS: overall survival. *Adjusted for conditioning intensity, disease status prior to transplantation,
recipient age, Karnofsky Performance Status, donor type, graft-versus-host disease prophylaxis, as applicable based on the individual models. §Except for those included in the
adverse and favorable groups
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with IGH-MYC) and CRLF2 have also been reported to
yield poor outcomes.24-26
Our study confirmed the previously established unfavorable risk associated with a complex karyotype6,27 after
allogeneic HCT. Notably, we observed substantial overlap
between complex karyotype, monosomal karyotype, and
other common abnormalities, mandating careful data
analysis and interpretation of complex cytogenetics in
future studies.
Monosomy 7 was consistently associated with worse
post-transplant outcomes in this and prior studies.8
Multiple mechanisms have been proposed to explain the
effects of monosomy 7 on leukemogenesis including, but
not limited to, loss of tumor suppressor genes, haploinsufficiency, or monoallelic loss of IKZF1, an important
adverse prognostic marker in B-cell ALL which is localized
to chromosome 7p.28,29 Haploinsufficient deletions of
IKZF1 are enriched among Ph– ALL cases and associated
with inferior survival.30
Our observed higher risk of relapse among allogeneic
HCT recipients with t(11;19) was also consistent with the
previously reported poor survival of ALL patients with
t(11;19)(q23;p13.3).31
We propose an allogeneic HCT-specific cytogenetic risk
classification for Ph– ALL separating patients into three
prognostic risk categories based on the presence of monosomy 7, del(7q), t(8;14), t(11;19), del(11q), complex,
tetraploid/near triploid, and high hyperdiploid karyotypes
(Table 5). This novel CIBMTR ALL risk classification of
Ph– patients treated with allogeneic HCT is directly relevant to pre-HCT decision-making and might help in stratifying clinical trial candidates undergoing allogeneic HCT
for Ph– ALL.
Unfortunately we could not account in our analysis for
pre-transplant minimal residual disease (MRD), defined
by flow cytometry or FISH/molecular testing. Pre-transplant MRD has been important in predicting ALL relapse
and future research should combine cytogenetic classifications with pre-transplant MRD status. Pretreatment complex karyotype and low hypodiploidy/near-triploidy portended poor survival after adjustment for MRD in a recent
single-institution study.27 Our analysis validated other
established patient- and transplant-related prognostic factors and thereby confirmed the additional importance of
the cytogenetic groupings. As most patients in this cohort
received allografts with myeloablative conditioning,
future validation of the CIBMTR ALL risk scheme among
recipients treated with reduced intensity conditioning will
test this prognostic tool in older and/or less fit ALL
patients.
Our study focused on the transplant period preceding
Food and Drug Administration approvals and broader use
of liposomal vincristine, blinatumomab, inotuzumab
ozogamycin, or tisagenlecleucel, and it thereby focused on
a more homogeneous patient population with no differen-
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